Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 14 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Karagiannis, Thomas  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
Karagiannis, T., Paschos P., Paletas K., Matthews D. R., & Tsapas A. (2012).  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.. BMJ. 344, e1369.
Karagiannis, T., Avgerinos I., Liakos A., Del Prato S., Matthews D. R., Tsapas A., et al. (2022).  Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.. Diabetologia. 65(8), 1251-1261.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence. Volume 12, 1 - 10.
Karagiannis, T., Tsapas A., Bekiari E., Toulis K. A., & Nauck M. A. (2024).  A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.. Diabetes Care. 47(2), 184-192.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.. Core Evid. 12, 1-10.
Karagiannis, T., Liakos A., Branda M. E., Athanasiadou E., Mainou M., Boura P., et al. (2016).  Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. BMJ Open. 6(11), e012185.
Karagiannis, T., Bekiari E., & Tsapas A. (2023).  Socioeconomic aspects of incretin-based therapy.. Diabetologia. 66(10), 1859-1868.
Karagiannis, T., Liakos A., Branda M. E., Athanasiadou E., Mainou M., Boura P., et al. (2016).  Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial.. BMJ Open. 6(11), e012185.
Karagiannis, T., Bekiari E., Boura P., & Tsapas A. (2016).  Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
Karagiannis, T., Tsapas A., & Bekiari E. (2021).  KDIGO made 12 recommendations for managing diabetes with CKD.. Ann Intern Med. 174(3), JC26.
Karagiannis, T., & Bekiari E. (2016).  Most add-on therapies to metformin have similar effects on HbA1c.. Evid Based Med. 21(6), 223.
Karagiannis, T., Boura P., & Tsapas A. (2014).  Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.. Ther Adv Drug Saf. 5(3), 138-46.
Karagiannis, T., Tsapas A., Athanasiadou E., Avgerinos I., Liakos A., Matthews D. R., et al. (2021).  GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.. Diabetes Res Clin Pract. 174, 108737.
Karagiannis, T., Bekiari E., Boura P., & Tsapas A. (2016).  Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.. Ther Adv Drug Saf. 7(2), 36-8.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές